Rivaroxaban, a direct inhibitor of activated coagulation factor X (FXa), has been approved for several cardiovascular indications including the prevention and treatment of venous thromboembolism, stroke prophylaxis in nonvalvular atrial fibrillation, and to reduce the risk of major cardiovascular events in coronary heart or peripheral artery disease [1]. Here, F10 is linked to peripheral arterial disease.